pegloticase

Also known as Puricase, Krystexxa, PEG-uricase

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not effective or are not tolerated. The drug is administered by infusion intravenously. Since October 2023, Amgen Inc. has been the marketer of pegloticase in the U.S.

In the Vinony graph

Within Vinony's link graph, pegloticase is referenced by 30 other articles, and connects out to UOX, pig and International Standard Book Number.

It is catalogued under topics including Antigout agents, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.

Its subject is documented across 9 Wikipedia language editions.

Chemical data

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Enzyme
First approval: 2010
Admin. routes: parenteral
Indications: gout, chronic kidney disease

via ChEMBL · EBI

Wikidata facts

Has use: medication

Show 5 more facts

defined daily dose: 0.57
subject has role: enzyme activator
medical condition treated: gout
has characteristic: biopharmaceutical
legal status (medicine): boxed warning

Sources (5)

via Wikidata · CC0

~3 min read

Encyclopedic overview

6 sections

Contents

Medical uses
Side effects
Mechanism of action
Chemistry
References
External links

It was developed by Savient Pharmaceuticals. It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue. The European Medicines Agency (EMA) granted marketing authorization in 2013 for treatment of disabling tophaceous gout. In 2016 this authorization was ended at the request of Horizon Therapeutics PLC in Europe.

Excerpted from Wikipedia’s “pegloticase” article, available under the CC BY-SA 4.0 licence.